A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation

Journal of Allergy and Clinical Immunology

Volumn 126, Issue 6, 2010, Pages

  López Lera, Alberto ^a,b,c   Favier, Bertrand ^d   De La Cruz, Rocío Mena ^a,b,c   Garrido, Sofía ^a,c   Drouet, Christian ^d   López Trascasa, Margarita ^a,b,c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d LABORATOIRE TIMC IMAG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARGININE 378; COMPLEMENT COMPONENT C1S INHIBITOR; KALLIKREIN; KININ; MUTANT PROTEIN; STANOZOLOL; UNCLASSIFIED DRUG;

ADULT; ANGIONEUROTIC EDEMA; CASE REPORT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FACE EDEMA; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HOMOZYGOTE; HUMAN; LARYNX EDEMA; LETTER; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BINDING;

EID: 78649900635     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.07.037     Document Type: Article

References (13)

1. S. Grigoriadou, and H.J. Longhurst Clinical immunology review series: an approach to the patient with angio-oedema Clin Exp Immunol 155 2009 367 377
2. M. Cugno, R. Castelli, and M. Cicardi Angioedema due to acquired C1-Inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation Autoimmun Rev 8 2008 156 159
3. M. Cugno, A. Zanichelli, F. Foieni, S. Caccia, and M. Cicardi C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress Trends Mol Med 15 2009 69 78
4. E. Eldering, E. Verpy, D. Roem, T. Meo, and M. Tosi COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization J Biol Chem 270 1995 2579 2587
5. A. Blanch, O. Roche, I. Urrutia, P. Gamboa, G. Fontán, and M. López-Trascasa First case of homozygous C1 inhibitor deficiency [published erratum in J Allergy Clin Immunol 2007;119:745] J Allergy Clin Immunol 118 2006 1330 1335
6. G. Vinci, N.J. Lynch, C. Duponchel, T.M. Lebastard, G. Milon, and C. Stover In vivo biosynthesis of endogenous and of human C1 inhibitor in transgenic mice: tissue distribution and colocalization of their expression J Immunol 169 2002 5948 5954
7. J.H. Nuijens, C.C. Huijbregts, G.M. van Mierlo, and C.E. Hack Inactivation of C1-inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C1-inhibitor Immunology 61 1987 387 389
8. J.A. Gelfand, R.J. Sherins, D.W. Alling, and M.M. Frank Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities N Engl J Med 295 1976 1444 1448
9. E. Pappalardo, L.C. Zingale, and M. Cicardi Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with danazol Immunol Lett 86 2003 271 276
10. S. Janciauskiene, S. Eriksson, F. Callea, M. Mallya, A. Zhou, and K. Seyama Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin Hepatology 40 2004 1203 1210
11. J.J. Wisnieski, T.C. Knauss, I. Yike, D.G. Dearborn, R.L. Narvy, and G.B. Naff Unique C1 inhibitor dysfunction in a kindred without angioedema, I: A mutant C1 INH that inhibits C1-s but not C1-r J Immunol 152 1994 3199 3209
12. R. Zahedi, J.J. Bissler, A.E. Davis 3rd, C. Andreadis, and J.J. Wisnieski Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443→Val substitution and functional analysis of the recombinant mutant protein J Clin Invest 95 1995 1299 1305
13. R. Zahedi, J.J. Wisnieski, and A.E. Davis 3rd Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases J Immunol 159 1997 983 988